Abstract
Purpose: The development of immune-related adverse events (irAEs) in patients undergoing immunotherapy has been reported to be a favorable prognostic factor in several studies. We aimed to examine the correlation between irAEs and prognosis in patients with non-small cell lung cancer (NSCLC) and further reveal the patient characteristics associated with response to immunotherapy among treatment responders who developed irAEs. Methods: We retrospectively enrolled 80 patients with NSCLC who received immunotherapy at Shinshu University Hospital between February 2016 and February 2020. Progression-free survival (PFS) and overall survival (OS) were compared between patients with and those without irAEs. We examined the prognostic factors associated with PFS and OS using univariate and multivariate Cox proportional-hazards models. We further analyzed the patients who developed irAEs by classifying them into responders and non-responders. Results: Twenty-five patients developed irAEs. The median PFS and OS of the patients with irAEs were significantly longer than those of the patients without irAEs (6.8 vs. 1.9 months, p < 0.001, and 37.8 vs. 8.1 months, p < 0.001, respectively). Multivariate analysis associated with PFS and OS indicated that the development of irAEs was an independent favorable prognostic factor. Among the patients developing irAEs, the responder group had a significantly higher incidence of multiple irAEs than the non-responder group (41.7 vs. 0.0%, p = 0.009). Conclusion: Our findings revealed that the development of irAEs was associated with clinical benefits in NSCLC patients who received immunotherapy. In particular, patients with multiple irAEs might have good prognoses.
References
1.
Miller
KD
, Nogueira
L
, Mariotto
AB
, Rowland
JH
, Yabroff
KR
, Alfano
CM
, et al. Cancer treatment and survivorship statistics, 2019
. CA Cancer J Clin
. 2019 Sep
;69
(5
):363
–85
. .2.
Brahmer
J
, Reckamp
KL
, Baas
P
, Crinò
L
, Eberhardt
WE
, Poddubskaya
E
, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
. N Engl J Med
. 2015 Jul
;373
(2
):123
–35
. .3.
Borghaei
H
, Paz-Ares
L
, Horn
L
, Spigel
DR
, Steins
M
, Ready
NE
, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
. N Engl J Med
. 2015 Oct
;373
(17
):1627
–39
. .4.
Herbst
RS
, Baas
P
, Kim
DW
, Felip
E
, Pérez-Gracia
JL
, Han
JY
, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
. Lancet
. 2016 Apr
;387
(10027
):1540
–50
. .5.
Rittmeyer
A
, Barlesi
F
, Waterkamp
D
, Park
K
, Ciardiello
F
, Von Pawel
J
, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
. Lancet
. 2017 Jan
;389
(10066
):255
–65
. .6.
Antonia
SJ
, Borghaei
H
, Ramalingam
SS
, Horn
L
, De Castro Carpeño
J
, Pluzanski
A
, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
. Lancet Oncol
. 2019
;20
(10
):1395
–408
. .7.
Spain
L
, Diem
S
, Larkin
J
. Management of toxicities of immune checkpoint inhibitors
. Cancer Treat Rev
. 2016 Mar
;44
:51
–60
. 8.
Diem
S
, Schmid
S
, Krapf
M
, Flatz
L
, Born
D
, Jochum
W
, et al. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
. Lung Cancer
. 2017 Sep
;111
:176
–81
. .9.
Mezquita
L
, Auclin
E
, Ferrara
R
, Charrier
M
, Remon
J
, Planchard
D
, et al. Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer
. JAMA Oncol
. 2018 Mar
;4
(3
):351
–7
. .10.
Haratani
K
, Hayashi
H
, Chiba
Y
, Kudo
K
, Yonesaka
K
, Kato
R
, et al. Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer
. JAMA Oncol
. 2018 Mar
;4
(3
):374
–8
. .11.
Toi
Y
, Sugawara
S
, Kawashima
Y
, Aiba
T
, Kawana
S
, Saito
R
, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab
. Oncologist
. 2018 Nov
;23
(11
):1358
–65
. .12.
Baldini
E
, Lunghi
A
, Cortesi
E
, Turci
D
, Signorelli
D
, Stati
V
, et al. Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: the Italian NSCLC expanded access program
. Lung Cancer
. 2020 Feb
;140
:59
–64
. .13.
Akamatsu
H
, Murakami
E
, Oyanagi
J
, Shibaki
R
, Kaki
T
, Takase
E
, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer
. Oncologist
. 2020 Apr
;25
(4
):e679
–83
. .14.
Eisenhauer
EA
, Therasse Bogaerts
PJ
, Bogaerts
J
, Schwartz
LH
, Sargent
D
, Ford
R
, et al. New Response Evaluation Criteria in Solid Tumours: revised RECIST guideline (version 1.1)
. Eur J Cancer
. 2009 Jan
;45
(2
):228
–47
. .15.
US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. 2018. Available from: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm.
16.
Das
S
, Johnson
DB
. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
. J Immunother Cancer
. 2019 Nov
;7
(1
):306
. .17.
Hosoya
K
, Fujimoto
D
, Morimoto
T
, Kumagai
T
, Tamiya
A
, Taniguchi
Y
, et al. Association between early immune-related adverse events and clinical outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
. Clin Lung Cancer
. 2020 Jul
;21
(4
):e315
–28
. .18.
Hasan Ali
O
, Diem
S
, Markert
E
, Jochum
W
, Kerl
K
, French
LE
, et al. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer
. Oncoimmunology
. 2016
;5
(11
):e1231292
. .19.
Osorio
JC
, Ni
A
, Chaft
JE
, Pollina
R
, Kasler
MK
, Stephens
D
, et al. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer
. Ann Oncol
. 2017
;28
(3
):583
–9
. .20.
Toi
Y
, Sugawara
S
, Sugisaka
J
, Ono
H
, Kawashima
Y
, Aiba
T
, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer
. JAMA Oncol
. 2019
;5
(3
):376
–83
. .21.
Felip
E
, Ardizzoni
A
, Ciuleanu
T
, Cobo
M
, Laktionov
K
, Szilasi
M
, et al. CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
. Eur J Cancer
. 2020
;127
:160
–72
. .22.
Muchnik
E
, Loh
KP
, Strawderman
M
, Magnuson
A
, Mohile
SG
, Estrah
V
, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer
. J Am Geriatr Soc
. 2019
;67
(5
):905
–12
. .23.
Lee
CK
, Man
J
, Lord
S
, Cooper
W
, Links
M
, Gebski
V
, et al. Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis
. JAMA Oncol
. 2018
;4
(2
):210
–6
. .24.
Meyers
DE
, Stukalin
I
, Vallerand
IA
, Lewinson
RT
, Suo
A
, Dean
M
, et al. The lung immune prognostic index discriminates survival outcomes in patients with solid tumors treated with immune checkpoint inhibitors
. Cancers (Basel)
. 2019
;11
(11
):1713
. .25.
Ricciuti
B
, Genova
C
, De Giglio
A
, Bassanelli
M
, Dal Bello
MG
, Metro
G
, et al. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
. J Cancer Res Clin Oncol
. 2019 Feb
;145
(2
):479
–85
. .26.
Shimozaki
K
, Sukawa
Y
, Beppu
N
, Kurihara
I
, Suzuki
S
, Mizuno
R
, et al. Multiple immune-related adverse events and anti-tumor efficacy: real-world data on various solid tumors
. Cancer Manag Res
. 2020 June
;12
:4585
–93
. © 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
